Primary and booster vaccination in reducing severe clinical outcomes associated with Omicron Naive infection.

ABSTRACT:

Background

Little is known about long-term effectiveness of COVID-19 vaccine in reducing severity and deaths associated with Omicron VOC not perturbed by prior infection and independent of oral anti-viral therapy and non-pharmaceutical (NPI).

Methods

A retrospective observational cohort study was applied to Taiwan community during the unprecedent large-scale outbreaks of Omicron BA.2 between April and August, 2022. Primary vaccination since March, 2021 and booster vaccination since January, 2022 were offered on population level. Oral Anti-viral therapy was also offered as of mid-May 2022. The population-based effectiveness of vaccination in reducing the risk of moderate and severe cases of and death from Omicron BA.2 with the consideration of NPI and oral anti-viral therapy

SUBMITTER: Hsu CY 

PROVIDER: S-EPMC9708104 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature